Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
4.400
-0.090 (-2.00%)
At close: Feb 21, 2025, 4:00 PM
4.369
-0.031 (-0.70%)
After-hours: Feb 21, 2025, 7:24 PM EST
Clover Health Investments Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Clover Health Investments stock have an average target of 5.00, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 13.64% from the current stock price of 4.40.
Analyst Consensus: Buy
* Price targets were last updated on Dec 17, 2024.
Analyst Ratings
The average analyst rating for Clover Health Investments stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +36.36% | Dec 17, 2024 |
| UBS | UBS | Hold Initiates $4 | Hold | Initiates | $4 | -9.09% | Oct 7, 2024 |
| Citigroup | Citigroup | Hold Maintains $1 → $1.5 | Hold | Maintains | $1 → $1.5 | -65.91% | Aug 11, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | -31.82% | Mar 6, 2023 |
| Credit Suisse | Credit Suisse | Sell Maintains $2.5 → $1.25 | Sell | Maintains | $2.5 → $1.25 | -71.59% | Mar 6, 2023 |
Financial Forecast
Revenue This Year
1.55B
Revenue Next Year
1.75B
from 1.55B
Increased by 13.05%
EPS This Year
-0.12
from -0.44
EPS Next Year
-0.14
from -0.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.2B | 2.3B | 2.1B | |||
| Avg | 1.5B | 1.8B | 1.9B | |||
| Low | 1.4B | 1.5B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 50.6% | 18.9% | |||
| Avg | - | 13.0% | 9.4% | |||
| Low | - | -4.1% | -0.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.12 | -0.07 | -0.08 | ||
| Avg | -0.12 | -0.14 | -0.11 | ||
| Low | -0.12 | -0.18 | -0.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.